COPD and Asthma Devices Market: High-end Analysis of the Key Segments with Leading Manufacturers like Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Philips Healthcare and 3M Health Care

Global COPD and asthma devices market is expected to reach $41,355.2 million by 2022, according to a new report by Allied Market Research . The drug powder inhaler was the highest revenue-generating segment, accounting for over half of the share in 2015. This segment is expected to maintain its dominance throughout the forecast period.

Compressor nebulizers constitute around four-fifths share of the overall nebulizers market, owing to their perpetual usage in home healthcare medication and widespread availability across various regions. Nebulizers are electric- or battery-powered machines, which dispense the medication in the form of fine mist. They are used in home healthcare set-ups for debilitated patients, geriatric, and children. However, the large size of nebulizers.

The factors hampering the market growth include environmental concerns associated with metered dose inhalers (MDI) and high cost of selected inhalation devices. Regulatory authorities such as U.S. food and drug administration (USFDA) across several regions have banned the production and sales of MDIs, as they release environmentally hazardous gases such as chlorofluorocarbon (CFC) and hydrofluoroalkanes (HFA). Thus, soft mist inhalers (SMIs) and nebulizers are expected to replace MDIs for the treatment of respiratory diseases in the near future.

Get sample copy of this report at:
www.alliedmarketresearch.com/request-sample/579?utm_source=PC_OPR

North America is expected to remain the highest revenue-generating region, owing to widespread and early adoption of inhalers & nebulizers and large pool of patients suffering from respiratory diseases. Moreover, the Asia-Pacific region is expected to grow rapidly due to rising healthcare expenditure, growing awareness of advanced portable COPD & asthma devices, and increasing disposable income.

Key players:

• GlaxoSmithKline Plc
• Novartis AG
• Merck & Co.Inc.
• AstraZeneca Plc
• Philips Healthcare
• 3M Health Care
• Allied Healthcare ProductsInc.
• Sunovion Pharmaceuticals Inc.
• GF Healthcare Products
• Smith Medicals Inc.
• Lincare Holdings Inc.
• Baxter International.

Key findings of COPD and Asthma Devices Market:
• Drug powder inhalers (DPIs) segment is projected to grow at a significant CAGR of 5.7% during the forecast period.
• North America was the leading region in 2015, and is expected to continue its dominance throughout the analysis period.
• The COPD and asthma devices market in Europe is projected to grow at a CAGR of 6.1%.
• The compressor nebulizers segment is expected to register a CAGR of 5.4%.

Send Enquiry on this report @
www.alliedmarketresearch.com/purchase-enquiry/579?utm_source=PC_OPR

About Us:

Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1?855?550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.